poisar

Stocks · News reference

MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing

Benzinga Newsdesk

MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MPLT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — MapLight Therapeutics, Inc. (MPLT)

    Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    MPLT